Sign up
Pharma Capital

Antares Pharma shares rally sparked by deal with Pfizer

The company enters a deal to develop an injection product using an unnamed Pfizer drug
pills and hypodermic needle
Antares is a specialty pharmaceuticals company using auto-injection technology

Antares Pharma Inc (NASDAQ:ATRS) shares vaulted higher Monday, inspired by news that it has forged an agreement with Pfizer Inc (NYSE:PFE) to develop a combination drug-device rescue pen.

Shares of Antares climbed 8.9% to US$2.83 in premarket trading. The shares closed Friday down by 1.9% to US$2.60.

The rescue pen will use an auto-injector and an undisclosed Pfizer drug. Pfizer will pay for development of the product and is responsible for obtaining US Food and Drug Administration approval for the device.

Under the supply agreement, Antares will provide a fully packaged, commercial-ready, finished product to Pfizer at cost and the margin, while Pfizer is responsible for commercializing the product in the US.

Antares will receive royalties on net sales of the combined product.

Antares is a specialty pharmaceuticals company using auto-injection technology.


Register here to be notified of future Company articles
View full profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.